Academic Journal
Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline
| العنوان: | Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline |
|---|---|
| المؤلفون: | Alavian, SM, Hajarizadeh, B, Lankarani, KB, Sharafi, H, Daryani, NE, Merat, S, Mohraz, M, Mardani, M, Fattahi, MR, Poustchi, H, Nikbin, M, Nabavi, M, Adibi, P, Ziaee, M, Behnava, B, Rezaee-Zavareh, MS, Colombo, M, Massoumi, H, Bizri, AR, Eghtesad, B, Amiri, M, Namvar, A, Hesamizadeh, K, Malekzadeh, R |
| المصدر: | urn:ISSN:1735-143X ; urn:ISSN:1735-3408 ; Hepatitis Monthly, 16, 8, e40959 |
| بيانات النشر: | Briefland |
| سنة النشر: | 2016 |
| المجموعة: | UNSW Sydney (The University of New South Wales): UNSWorks |
| مصطلحات موضوعية: | Digestive Diseases, Chronic Liver Disease and Cirrhosis, Infectious Diseases, Hepatitis - C, Emerging Infectious Diseases, Hepatitis, Liver Disease, Infection, 3 Good Health and Well Being, Consensus, Disease Elimination, Hepatitis C, Iran, Therapy, anzsrc-for: 1103 Clinical Sciences, anzsrc-for: 1117 Public Health and Health Services |
| الوصف: | Context: Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran. Evidence Acquisition: The recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, ScopusandWeb of Science. Expert opinionwasbasedonthe consensus of Iran Hepatitis Scientific Board (IHSB) in the 3rd national consensus on management of Hepatitis C in Iran, held on 22nd of July 2016. Results: Pegylated Interferon alpha (PegIFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV) and Daclatasvir (DCV) are currently available in Iran. Pre-treatment assessments include HCV RNA level, HCV genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. InHCVgenotype 1 and 4, DCV/SOF and LDV/SOF are recommended. InHCVgenotype 2, SOF plus RBV and inHCVgenotype 3, DCV/SOF is recommended. Additional care for underlying diseases should be considered. Conclusions: Affordable new HCV treatment regimens are available in Iran, providing an opportunity for HCV elimination. Recommendations provided in this current national guideline can facilitate evidence-based management of HCV infection. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| Relation: | http://purl.org/au-research/grants/nhmrc/APP1112512; http://hdl.handle.net/1959.4/unsworks_42578; https://doi.org/10.5812/hepatmon.guideline |
| DOI: | 10.5812/hepatmon.guideline |
| الاتاحة: | http://hdl.handle.net/1959.4/unsworks_42578 https://doi.org/10.5812/hepatmon.guideline |
| Rights: | open access ; https://purl.org/coar/access_right/c_abf2 ; CC BY-NC ; https://creativecommons.org/licenses/by-nc/4.0/ |
| رقم الانضمام: | edsbas.DE50DD49 |
| قاعدة البيانات: | BASE |
| DOI: | 10.5812/hepatmon.guideline |
|---|